V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryHBEL / PDE in Shared Supplement Facilities
Quality · The complete guide

HBEL / PDE in Shared Supplement Facilities

In short

A health-based exposure limit (HBEL), most often expressed as a Permitted Daily Exposure (PDE), is a toxicology-derived safe threshold for a residual active substance — and since the EMA's 2014 guideline it has steadily replaced flat conventions like 10 ppm or 1/1000th of a dose as the basis for cleaning limits and dedicated-facility decisions in shared manufacturing.

3,663 words · ~17 min read
Health-based exposure limits: two adjacent production rooms, swab sampling of a steel surface, a microscope and a toxicology report
An HBEL/PDE sets the health-based residue limit used in shared-facility cleaning limits.
On this page
  1. 01Why regulators moved on from 10 ppm and 1/1000th of a dose
  2. 02The EMA guideline and the PDE calculation
  3. 03EU GMP Chapter 3 and Chapter 5: where the requirement actually sits
  4. 04The 2018 Q&A: closing the implementation gaps
  5. 05PIC/S adoption
  6. 06How the HBEL/PDE feeds cleaning validation and MACO
  7. 07Worst-case product selection and swab limits in practice
  8. 08Application to dietary supplement and contract manufacturing facilities
  9. 09Operations: documenting product-specific HBELs
On this page · 9 sections
  1. 1Why regulators moved on from 10 ppm and 1/1000th of a dose
  2. 2The EMA guideline and the PDE calculation
  3. 3EU GMP Chapter 3 and Chapter 5: where the requirement actually sits
  4. 4The 2018 Q&A: closing the implementation gaps
  5. 5PIC/S adoption
  6. 6How the HBEL/PDE feeds cleaning validation and MACO
  7. 7Worst-case product selection and swab limits in practice
  8. 8Application to dietary supplement and contract manufacturing facilities
  9. 9Operations: documenting product-specific HBELs
AI · Explain it for MY operation

How does HBEL / PDE in Shared Supplement Facilities apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Why regulators moved on from 10 ppm and 1/1000th of a dose

For decades, cleaning validation limits in pharmaceutical and nutraceutical manufacturing rested on two conventions that had nothing to do with the toxicology of the specific substance involved: no more than 10 parts per million of the previous product carried into the next batch, and no more than 1/1000th of the lowest therapeutic dose of the previous product appearing in the maximum daily dose of the next. Both rules of thumb are easy to calculate and easy to audit, which is why they spread so widely, but neither asks whether the residual substance is a mild vitamin, a potent hormone, or a beta-lactam capable of triggering a severe allergic reaction in trace amounts. A flat percentage or flat fraction-of-dose treats all actives the same regardless of their actual hazard.

The EMA's guideline frames the problem directly: when different medicinal products are produced in shared facilities, cross-contamination is a concern because the contaminating product provides no benefit to the patient receiving the next product, and may pose a risk. The guideline states that "the presence of such contaminants should be managed according to the risk posed which in turn are related to levels that can be considered safe for all populations," and that health-based limits derived from a structured scientific evaluation of all available pharmacological and toxicological data — not an arbitrary convention — should be used to identify those risks.

The guideline also records why the industry needed official help: certain classes of medicinal product — "certain antibiotics, certain hormones, certain cytotoxics and certain highly active drugs" — had historically been required to go into dedicated or segregated self-contained facilities, but until this guideline there was no official way to differentiate between individual products within those broad classes. A health-based number lets a manufacturer show that a specific molecule, at its specific potency, does or does not need that level of segregation, rather than applying a blanket rule to an entire drug class.

HBEL and PDE are not interchangeable labels for the same thing

HBEL is the general concept — a health-based threshold for safe exposure to a given substance. PDE is one specific method of calculating that threshold (borrowed from the ICH Q3C residual-solvents framework), expressed in mg or µg per day. The EMA guideline also mentions the Threshold of Toxicological Concern (TTC) as an alternative approach where full toxicological data are unavailable. Most cleaning-validation programmes in practice work with the PDE.

02The EMA guideline and the PDE calculation

The controlling EU document is EMA/CHMP/CVMP/SWP/169430/2012, "Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities." It was agreed by the Safety Working Party in draft in December 2012, went out for consultation through mid-2013, was adopted by CVMP on 11 September 2014 and by CHMP on 20 November 2014, and came into effect on 1 June 2015. It applies to both human and veterinary medicinal products.

Section 4.1 states that the guideline's procedure for a residual active substance is based on the method for establishing a Permitted Daily Exposure (PDE) as described in Appendix 3 of ICH Q3C(R4), "Impurities: Guideline for Residual Solvents," and the equivalent appendix of VICH GL18 for veterinary products. The PDE is defined as "a substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime." Deriving one involves, in the guideline's own sequence: (i) hazard identification by reviewing all relevant non-clinical and clinical data; (ii) identification of the "critical effects" — the most sensitive, relevant adverse findings; (iii) determination of the no-observed-adverse-effect level (NOAEL, or in some cases a lowest-observed-adverse-effect level, LOAEL) for those critical effects; and (iv) application of several adjustment factors to account for uncertainty.

The guideline reproduces the ICH Q3C/VICH GL18 equation as: PDE = (NOAEL × weight adjustment) ÷ (F1 × F2 × F3 × F4 × F5). The five adjustment factors (F1–F5) scale the NOAEL down to account for things such as interspecies extrapolation, variability between individuals, the nature and severity of the toxic effect, the duration of the study relative to a lifetime, and the absence of a NOAEL where a LOAEL had to be used instead — each factor's specific value and justification sit in the ICH Q3C(R4)/VICH GL18 reference text that the EMA guideline incorporates, rather than being restated wholesale inside the EMA guideline itself. The guideline directs that the PDE should be calculated on a mg/kg bodyweight basis (a weight-adjustment figure of 1) rather than per person, and — pragmatically, because deriving a separate PDE for every target animal species would be impractical — that PDEs should generally be derived assuming human exposure even when the carrying-over product is a veterinary medicine. Alternative approaches, including benchmark-dose methods instead of a NOAEL, may be used if scientifically justified.

Hazard identification itself draws on non-clinical pharmacodynamic data, repeat-dose toxicity studies, carcinogenicity studies, in vitro and in vivo genotoxicity studies, reproductive and developmental toxicity studies, and clinical data on therapeutic and adverse effects — the guideline expects a structured review of whatever is available for the specific compound, not a single study in isolation.

The derivation needs a named, competent assessor — not a purchased number

The companion Q&A document states that HBELs should be determined by a person with adequate expertise and experience in toxicology or pharmacology, familiarity with pharmaceuticals, and experience setting health-based limits such as Occupational Exposure Levels or PDEs. Where that expertise is contracted out, a Chapter 7-compliant technical agreement should be in place before the work starts, and it is explicitly "not considered acceptable for manufacturers to 'purchase' HBEL assessments without recording an assessment of the suitability of the provider."

03EU GMP Chapter 3 and Chapter 5: where the requirement actually sits

The EMA scientific guideline sets out the method; the binding obligation to use it sits in EudraLex Volume 4 itself. Chapter 3 ("Premises and Equipment") of Part I was revised, alongside Chapter 5 ("Production"), with a reasons-for-change note stating that "the only change is to section 6 as part of the improved guidance on prevention of cross-contamination involving also Chapter 5." The revised text came into operation on 1 March 2015 for most provisions, but the toxicological evaluation requirement specifically was phased in on a schedule tied to the EMA guideline's own effective date: from 1 June 2015 for any medicinal product newly introduced into a shared facility; before 1 December 2015 for products already in a shared human (or combined human/veterinary) facility as of 31 May 2015; and before 1 June 2016 for veterinary-only shared facilities.

Chapter 3, section 3.6 states the governing principle: "Cross-contamination should be prevented for all products by appropriate design and operation of manufacturing facilities. The measures to prevent cross-contamination should be commensurate with the risks. Quality Risk Management principles should be used to assess and control the risks." It then sets out, verbatim, the three conditions under which dedicated facilities are required for manufacturing:

  1. the risk cannot be adequately controlled by operational and/or technical measures,
  2. scientific data from the toxicological evaluation does not support a controllable risk (the chapter's own example: allergenic potential from highly sensitising materials such as beta-lactams), or
  3. relevant residue limits, derived from the toxicological evaluation, cannot be satisfactorily determined by a validated analytical method.

Chapter 3 points onward to Chapter 5 and Annexes 2–6 for further detail. Chapter 5's Production section works through the operational and technical controls expected before a product is deemed suitable for shared equipment at all — segregation in time or space, airlocks and pressure cascades, dedicated or single-use equipment components, closed processing, and campaign working among them — with the toxicological evaluation and resulting HBEL used as the risk-identification input that determines how far along that spectrum of control a given product needs to sit.

DocumentRole
EudraLex Vol. 4, Part I, Chapter 3 §3.6States the binding GMP obligation and the three conditions requiring dedicated facilities
EudraLex Vol. 4, Part I, Chapter 5Sets out operational/technical controls for shared production and links them to the toxicological evaluation
EMA/CHMP/CVMP/SWP/169430/2012Scientific method for calculating the HBEL/PDE that feeds the Chapter 3/5 risk assessment
EMA/CHMP/CVMP/SWP/246844/2018 (Q&A)Clarifies implementation questions raised by industry and inspectors after the 2015 phase-in

04The 2018 Q&A: closing the implementation gaps

Within a few years of the Chapter 3/5 changes, manufacturers and inspectors had enough practical experience with HBELs to surface recurring questions, and EMA published a dedicated Q&A, EMA/CHMP/CVMP/SWP/246844/2018, dated 19 April 2018, jointly from CHMP and CVMP. It opens with the question of scope: "Are Health-Based Exposure Limits (HBELs) required for all medicinal products?" Its answer is unambiguous — "Yes, HBELs should be established for all medicinal products" — and adds that the underlying toxicological or pharmacological data need periodic reassessment across a product's lifecycle, not a one-time calculation at launch.

The Q&A is explicit that a higher HBEL (a less hazardous substance) warrants lighter controls and a lower HBEL (a more hazardous substance) warrants more elaborate organisational and technical measures, following a structured Quality Risk Management process rather than fixed cut-off points: "hazard varies on a continuum scale and there are no firm cut off points, risk should be controlled on a proportionate basis." Crucially, it states what happens when controls cannot keep contamination below the HBEL with consistency: "Where control measures cannot adequately assure that the potential contamination is consistently controlled to a level below that of the HBEL then the products concerned should be manufactured in dedicated facilities." That is the general-purpose trigger for dedicated manufacturing, alongside the beta-lactam/sensitiser and non-measurable-residue examples named directly in Chapter 3.

On the cleaning-limit question specifically, the Q&A pulls back from a common misreading of the 2012 guideline. It confirms the EMA guideline "may be used to justify cleaning limits" but states plainly that "it is not intended to be used to set cleaning limits at the level of the calculated HBEL." For existing products, the Q&A says manufacturers' historically used cleaning limits can be retained as alert limits, provided those limits — taking the cleaning process's demonstrated capability into account — give sufficient assurance that excursions above the HBEL will be prevented; the same logic applies when setting alert limits for a product entering a facility for the first time. Results above the alert limit should trigger investigation and, where warranted, corrective action; the Q&A adds that repeated excursions indicating the cleaning method is not in control will not be considered acceptable.

The Q&A also addresses analytical testing frequency at product changeover: it is expected at each changeover unless a documented Quality Risk Management process justifies otherwise, considering at minimum the repeatability of the cleaning process (manual methods generally being less repeatable than automated ones), the hazard posed by the product, and whether visual inspection can reliably confirm cleanliness at the HBEL-derived residue limit — tying visual-clean criteria back to the same toxicological threshold.

An HBEL is not the same number as a cleaning acceptance limit

Treating the calculated PDE itself as the swab or rinse pass/fail limit skips the margin that the HBEL is meant to protect. The Q&A's own guidance is to use historically demonstrated, capability-based alert limits under the HBEL, investigate excursions, and reserve dedicated facilities for cases where consistent control below the HBEL cannot be assured by any operational or technical measure.

05PIC/S adoption

The Pharmaceutical Inspection Co-operation Scheme transposed the EMA's 2012 guideline into its own guidance document, PI 046-1, adopted by the PIC/S Committee on 17–18 April 2018 and in force from 1 July 2018. PIC/S documentation records it as adapted from EMA/CHMP/CVMP/SWP/169430/2012 by the PIC/S Sub-Committee on the Harmonisation of GM(D)P, noting that each PIC/S Participating Authority decides for itself whether to make the guidance legally binding in its own jurisdiction. PIC/S followed the same pattern for the 2018 EMA Q&A, publishing PI 053-1 (in force 1 June 2020) as its own transposed Q&A, and issued a companion inspection aide-memoire, PI 052-1, on inspecting HBEL assessments and their use in Quality Risk Management — developed by the PIC/S Expert Circle on Controlling Cross-Contamination in Shared Facilities, led by the UK's MHRA.

Because PIC/S membership spans regulators well beyond the EU/EEA, this transposition is the mechanism by which the EMA's HBEL/PDE approach has become the de facto reference point for inspectors in many non-EU jurisdictions reviewing shared-facility cross-contamination controls, even where the underlying EudraLex Chapter 3/5 text is not itself the applicable local law.

06How the HBEL/PDE feeds cleaning validation and MACO

Once a PDE exists for an active substance, it becomes one input into the Maximum Allowable Carryover (MACO) calculation that sets the swab or rinse acceptance limit for cleaning validation on shared equipment. Historically, MACO was calculated from the more conservative of the 10 ppm and 1/1000th-dose rules; current practice, reflecting the EMA guideline and Q&A, adds the HBEL/PDE as a third criterion and generally treats the PDE-based figure as the scientifically defensible ceiling, with the actual working cleaning (alert) limit set below it with margin for the cleaning process's demonstrated capability, as the Q&A describes.

Translating a PDE (expressed as a daily dose, e.g. µg/day) into a surface residue limit (µg/swab or µg/cm²) or a rinse concentration requires the shared equipment's batch size, the minimum daily dose of the next product manufactured on that equipment, shared surface area, and swab recovery data — the mechanics of that conversion, and the three-criteria comparison against 10 ppm and 1/1000th dose, are covered in detail in this glossary's MACO entry rather than restated here.

How V5 supports HBEL-driven cleaning limits

V5 lets quality teams attach a documented HBEL/PDE value, its derivation reference, and review date to each active substance record, link it to the equipment-group and worst-case product logic used in cleaning validation protocols, and flag swab or rinse results against the resulting alert limit automatically during batch review — with the underlying toxicological assessment and assessor credentials stored as supporting documentation, not just the final number.

07Worst-case product selection and swab limits in practice

Where a line manufactures several products in rotation, cleaning validation protocols conventionally pick a single "worst case" product to validate against, on the logic that if the cleaning procedure removes the hardest-to-clean, most hazardous residue to an acceptable level, it will also handle the others. Introducing HBEL/PDE data changes what "worst case" means in practice: a product is no longer automatically worst case just because it is hardest to dissolve or has the highest therapeutic dose — a low-PDE, highly potent or sensitising active can be worst case even in small quantities, because its acceptable residue level is far lower than a bulkier but less toxic product's.

Operationally, this means the worst-case assessment for a shared line should compare PDEs across every product that line runs, not just doses or solubility, and should be revisited whenever a new product (or a new HBEL for an existing product, following periodic reassessment) is introduced — consistent with the Q&A's statement that toxicological data require periodic reassessment throughout a product's lifecycle. Swab limits derived from the resulting MACO then need their own supporting data: validated swab recovery studies for the specific surface materials in the equipment train, and an analytical method with sufficient sensitivity to measure down to the HBEL-based limit, which the Q&A notes is itself one of the three conditions (alongside uncontrollable risk and high sensitisation) that can push a product into a dedicated facility if no method can reliably measure to the required limit.

08Application to dietary supplement and contract manufacturing facilities

EMA/CHMP/CVMP/SWP/169430/2012, Chapter 3 and Chapter 5 of EudraLex Volume 4, and the 2018 Q&A are written for, and legally bind, manufacturers of human and veterinary medicinal products within the EU GMP framework. Dietary supplement manufacturing is regulated differently — in the US under 21 CFR Part 111's cleaning and equipment provisions, and in the EU/UK under food-law frameworks rather than medicines GMP — so the HBEL/PDE methodology does not apply to supplement facilities as a direct legal requirement in the way it does to medicinal product manufacturers.

In practice, however, the HBEL/PDE approach has become a widely referenced best-practice framework for shared-equipment supplement and contract manufacturing operations, particularly where: a facility is a hybrid site manufacturing both pharmaceutical and supplement products on shared lines (in which case the pharmaceutical products pull the GMP obligation in regardless of what runs alongside them); a contract manufacturer serves pharmaceutical-adjacent or highly potent nutraceutical ingredients (for example certain botanicals with narrow margins of safety, or ingredients also used at pharmacological doses) where a flat 10 ppm or 1/1000th-dose rule would be a poor fit for the actual hazard; or a brand owner's quality agreement with its contract manufacturer explicitly specifies a toxicology-based cleaning limit as a condition of the business relationship, independent of what the applicable food-safety regulation technically requires.

Where a supplement or hybrid-facility contract manufacturer chooses to adopt the HBEL/PDE method voluntarily, the same documentation discipline the EMA Q&A describes for medicinal products — a named, suitably experienced assessor; a recorded derivation referencing the specific NOAEL/LOAEL study and adjustment factors used; and a periodic reassessment schedule — is the practical way to make the resulting number defensible to an auditor or brand-owner, even though no supplement-specific regulation mandates that exact process.

A supplement facility citing HBEL/PDE should document which parts it is actually applying

Because the EMA guideline, Chapters 3/5, and the Q&A are medicines-GMP documents, a supplement or contract manufacturer referencing them should be explicit in its own quality system about which elements it has voluntarily adopted (for example, the PDE calculation method and the dedicated-facility decision logic) rather than implying the facility is operating under EU medicines GMP as a whole.

09Operations: documenting product-specific HBELs

A defensible HBEL/PDE record, consistent with what the EMA guideline and Q&A describe, generally includes: the identity and qualifications of the assessor (or the contracted expert and the Chapter 7 technical agreement covering that work); the data set reviewed for hazard identification (non-clinical pharmacodynamic data, repeat-dose toxicity, carcinogenicity, genotoxicity, reproductive/developmental toxicity, and clinical data, as available); the critical effect(s) identified and the NOAEL or LOAEL selected; each adjustment factor applied (F1–F5) with its justification; the resulting PDE in mg/kg bodyweight and in a daily-dose figure; the date of derivation and the date (or trigger event) for the next scheduled reassessment; and, where the substance is handled across both human and veterinary product lines or by a contract manufacturer on behalf of multiple brand owners, a record of how the PDE was communicated to each affected party.

The Q&A's Q5 is specific about that last point for contract manufacturing relationships: contract givers should either provide a full HBEL assessment to their contract manufacturer or provide the underlying data so the contract manufacturer can conduct its own assessment, and in either case the assessment — including data references and the relevant expert — should be available on request at inspection. A contract manufacturer that cannot produce this chain of documentation on request has, in effect, no defensible HBEL regardless of what number appears on a cleaning validation protocol.

Frequently asked questions

Q.What is the difference between an HBEL and a PDE?+

HBEL (health-based exposure limit) is the general concept of a toxicology-derived safe exposure threshold for a substance. PDE (Permitted Daily Exposure) is the specific calculation method the EMA guideline adopts from ICH Q3C(R4)/VICH GL18, expressed as a daily dose. The EMA guideline also allows the Threshold of Toxicological Concern (TTC) as an alternative where full toxicological data are unavailable.

Q.What is the PDE formula and what are F1–F5?+

The EMA guideline reproduces the ICH Q3C/VICH GL18 equation: PDE = (NOAEL × weight adjustment) ÷ (F1 × F2 × F3 × F4 × F5). F1–F5 are adjustment factors drawn from that ICH/VICH reference text that scale the NOAEL (or LOAEL) down for uncertainties such as interspecies extrapolation, inter-individual variability, the severity of the toxic effect, study duration relative to a lifetime, and use of a LOAEL instead of a NOAEL. Their specific definitions sit in ICH Q3C(R4)/VICH GL18 rather than being restated in full inside the EMA shared-facilities guideline.

Q.Does a PDE become the cleaning acceptance limit directly?+

No. The EMA Q&A (EMA/CHMP/CVMP/SWP/246844/2018, Q6) states the guideline "is not intended to be used to set cleaning limits at the level of the calculated HBEL." Manufacturers are expected to retain or establish alert limits below the HBEL, informed by the cleaning process's demonstrated capability, and investigate any result above the alert limit.

Q.When does EU GMP require a dedicated facility rather than shared equipment?+

EudraLex Volume 4, Part I, Chapter 3, section 3.6 sets out three conditions: the risk cannot be adequately controlled by operational or technical measures; the toxicological evaluation does not support a controllable risk (its example being allergenic potential from highly sensitising materials such as beta-lactams); or residue limits derived from the toxicological evaluation cannot be satisfactorily measured by a validated analytical method. The 2018 Q&A adds the general principle that where controls cannot consistently keep contamination below the HBEL, the product should move to a dedicated facility.

Q.Does the EMA HBEL guideline apply to dietary supplement manufacturing?+

Not as a legal requirement — it is part of the EU medicines GMP framework (EudraLex Volume 4) and binds manufacturers of human and veterinary medicinal products. Supplement and hybrid-facility contract manufacturers sometimes adopt the PDE methodology voluntarily, particularly for potent or sensitising ingredients, but should be explicit about which elements of the EMA framework they have adopted rather than implying the facility operates under EU medicines GMP generally.

Q.Who is allowed to determine an HBEL?+

The EMA Q&A states it should be a person with adequate expertise and experience in toxicology or pharmacology, familiarity with pharmaceuticals, and experience determining health-based limits such as Occupational Exposure Levels or PDEs. Contracted experts need a Chapter 7-compliant agreement in place before the work starts, and the assessment (with data references and the expert's identity) must be available on request at inspection.

Primary sources

  • EMA/CHMP/CVMP/SWP/169430/2012 — Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (PDF)
  • EudraLex Volume 4, Part I, Chapter 3 — Premises and Equipment (health.ec.europa.eu, 13 August 2014)
  • EMA/CHMP/CVMP/SWP/246844/2018 — Questions and answers on implementation of risk-based prevention of cross-contamination in production (PDF)

Further reading

  • MACO Cleaning Acceptance Criteria
    How the HBEL/PDE combines with 10 ppm and 1/1000th-dose criteria to set the actual swab or rinse limit.
  • Cleaning Validation
    The broader lifecycle this HBEL/PDE work feeds into, from worst-case selection to ongoing monitoring.
  • Cleaning Validation MAC
    The numerical acceptance criterion itself and how it is set in practice.
  • TOC Swab Vs. Rinse Sampling
    Sampling method choices that determine whether an HBEL-derived limit can actually be measured.
  • EU Annex 15 Qualification and Validation
    The validation lifecycle framework that cleaning validation studies sit within.
  • Contract Manufacturer Supplement
    How HBEL data and documentation obligations pass between contract givers and contract manufacturers.
Software that covers HBEL / PDE in Shared Supplement Facilities
V5 Ultimate Pharma 4.0 Platform
Connected execution, quality and lab records with AI-assisted drafting for CAPA and deviations, reviewed and signed by people, on…
V5 Ultimate Dietary Supplements
Written for supplement contract manufacturers and brand owners tired of surviving FDA 483s on paper.
Talk to us about HBEL / PDE in Shared Supplement Facilities

Want to see how HBEL / PDE in Shared Supplement Facilities could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Inside V5
  • → QMS — quality records next to the work they concern.
  • → Document control — one version in force, every change signed and explained.
  • → Score your compliance gap — then download the validation pack.
Regulatory anchors
  • EMA HBEL Guideline 2014
  • ISPE Risk-MaPP
Related terms
  • → MACO (Cleaning Acceptance Limit)

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC